• Levonorgestrel 52mg in a T-shaped intra-uterine system. 
• For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.

Approved Medroxyprogesterone formulations include:

• 2.5mg, 5mg, and 10mg tablets (sometimes used as a progestogen component of HRT).
• 100mg & 200mg tablets (for use in malignant disease see section 8.3.2).
• 50mg in ml injection - see sections 7.3.2.2 for use of  medroxyprogesterone acetate injection in contraception.

• 100mg oral capsules 
• Approved for:
  
  • adjunctive use with estrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT)
  • Perimenopause (off-label)
  • Premature ovarian insufficiency (off-label)
  • Adolescents undergoing pubertal induction following chemotherapy (off-label)
  
  
  

• Approved formulations include:
  
  • 200mg & 400mg pessaries (Cyclogest®) 
    • To support the pregnancies of women who have a history of miscarriage or premature labour as per NICE NG25: Preterm labour and birth AND NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management.
  • 200mg vaginal capsules (Utrogestran®) 
    • To support the pregnancies of women who have a history of miscarriage or premature labour as per NICE NG25: Preterm labour and birth AND NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management.
  • 25mg SC/IM injection (Lubion®) 
    
    • Approved for luteal support in patients who have had a previous failed biochemical pregnancy in a froxen embryo transfer (FET) cycle

• CD&TV  for Luteal Phase support following IVF.
  • Full course to be supplied by hospital

• 5mg tablets
  
  • Approved for the pre-operative treatment of uterine fibroids for one 3 month course, as per its product licence.
  • Approved for the medical treatment of uterine fibroids in women unsuitable for surgery, up to a maximum of four 3 month intermittent courses, as per its product licence and reviewed regularly.
  • Contraindicated in women with underlying liver disorders.  
  • Requirements for liver function monitoring before, during, and after treatment